Related Experiment Video
Updated: Aug 16, 2026

Wild-type Blocking PCR Combined with Sanger Sequencing for Detection of Low-frequency Somatic Mutation
Published on: August 23, 2024
Human T cell lymphotropic virus-associated leukemia/lymphoma
1Division of Molecular Oncology, Washington University, 660 South Euclid Avenue, Saint Louis, MO 63110, USA. lratner@im.wustl.edu
Purpose Of Review:
This article summarizes the current pathophysiologic basis for human T cell lymphotropic virus-associated leukemia/lymphoma as well as past, present, and future therapeutic options.
Recent Findings:
New studies have been published on allogeneic stem cell transplantation, arsenic trioxide, and bortezomib for this condition.
Summary:
Studies of the molecular biology of human T cell lymphotropic virus-1-induced T cell leukemia/lymphoma have defined a critical role for oncoprotein, Tax, and activation of nuclear factor kappaB transcription pathways, which have provided rational approaches to improved therapy for T cell leukemia/lymphoma as well as a model for other hematopoietic malignancies characterized by nuclear factor kappaB activation.
Related Concept Videos
Cytomegalovirus Disease
Mechanisms of Retrovirus-induced Cancers
Immunodeficiency Diseases
There are three main causes of immunodeficiency disorders...
